Articles related to PSYCHEDELICS

Recent phase 3 clinical trials have demonstrated the eye-opening potential of MDMA in the treatment of PTSD when paired with psychotherapy, providing a new method of patient care.

The preliminary findings suggest a potential new direction for managing chronic pain in PTSD, inviting further research and consideration in the clinical field.

AMA’s introduction of a CPT III code for psychedelic therapies denotes a potential paradigm shift in the treatment of mental health conditions, inviting clinicians to explore these emerging modalities.

Discover how the FDA’s first draft guidance on psychedelic drugs outlines a path for future medical treatments, addressing crucial considerations from study design to safety measures. Learn more about how this pivotal step could transform the therapeutic landscape.

This podcast tells the story of Sarah, a 32-year-old US government research scientist who was seriously injured on a bike ride in July 2001 and became completely bedridden as a result of a fractured spine, broken rib, concussion, torn tendons, and other injuries. When she moved again, she was in excruciating pain and wondered if she should even bother. A clinical trial then changed her life.

This brief editorial introduces a series of articles describing the medical use of hallucinogens, ketamine, marijuana, and other agents — including the legal and ethical perspectives — in the treatment of various neurologic and psychiatric disorders.